Masaharu Akiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masaharu Akiyama has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
Hisashi Yamada
Division of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan
13 shared publicationsKentaro Yokoi
Departments of Pediatrics
13 shared publicationsYoshikatsu Eto
Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan
11 shared publicationsKohji Fujisawa
Jikei University School of Medicine
9 shared publicationsTakaaki Yanagisawa
Dep of Paediatric Neuro-Oncology/Neurosurgery, Jikei University School of Medicine, Tokyo, Japan
9 shared publicationsHiroyuki Ida
Departments of Pediatrics
8 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Impact of Japan's 2024 Physician Work‐Style Reform on Pediatric Hematology–Oncology: Educational Implications in a 2‐Year Survey
Background: Japan's 2024 physician work‐style reform introduced legally binding limits on physicians’ working hours, but its impact on education and workforce sustainability in pediatric hematology–oncology (PHO) remains unclear. Procedure: We conducted a repeated cross‐sectional study with structured quantitative items and free‐text responses. The study was carried out at institutions participating in a Japanese multicenter PHO collaborative network. Participants were heads or designated representatives of PHO units at these facilities, with 27 responses obtained in 2023 and 35 in 2024. The main outcomes were perceived impacts of the reform on clinical services, staffing, education, research activities, and workforce sustainability. Results: In 2023, 15/27 (55.6%) participants anticipated that medical services would be affected by the 2024 work‐style reform; in 2024, 4/35 (11.4%) participants reported services were affected (29/35, 82.9% not affected; 2/35, 5.7% unsure). The impact on research or education was anticipated by 13/27 (48.1%) in 2023 and reported by 13/35 (37.1%) in 2024. In 2024, the main implementation problems were physician shortages (28/35, 80.0%) and limited task shifting or sharing (23/35, 65.7%). Free‐text responses highlighted reduced clinical clerkship for medical students and bedside teaching for residents, fewer after‐hours educational opportunities, and increased tasks as self‐directed learning, with concerns about uneven workloads among senior physicians. Conclusions: Although the reform was perceived to have limited immediate disruption of clinical services in 2024, a substantial minority of institutional representatives reported adverse effects on research or education and pervasive structural barriers. These perceived impacts on this specialist educational field warrant monitoring to safeguard future workforce capacity.
- 8 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Open AccessImpact of Japan's 2024 Physician Work‐Style Reform on Pediatric Hematology–Oncology: Educational Implications in a 2‐Year Survey
Background: Japan's 2024 physician work‐style reform introduced legally binding limits on physicians’ working hours, but its impact on education and workforce sustainability in pediatric hematology–oncology (PHO) remains unclear. Procedure: We conducted a repeated cross‐sectional study with structured quantitative items and free‐text responses. The study was carried out at institutions participating in a Japanese multicenter PHO collaborative network. Participants were heads or designated representatives of PHO units at these facilities, with 27 responses obtained in 2023 and 35 in 2024. The main outcomes were perceived impacts of the reform on clinical services, staffing, education, research activities, and workforce sustainability. Results: In 2023, 15/27 (55.6%) participants anticipated that medical services would be affected by the 2024 work‐style reform; in 2024, 4/35 (11.4%) participants reported services were affected (29/35, 82.9% not affected; 2/35, 5.7% unsure). The impact on research or education was anticipated by 13/27 (48.1%) in 2023 and reported by 13/35 (37.1%) in 2024. In 2024, the main implementation problems were physician shortages (28/35, 80.0%) and limited task shifting or sharing (23/35, 65.7%). Free‐text responses highlighted reduced clinical clerkship for medical students and bedside teaching for residents, fewer after‐hours educational opportunities, and increased tasks as self‐directed learning, with concerns about uneven workloads among senior physicians. Conclusions: Although the reform was perceived to have limited immediate disruption of clinical services in 2024, a substantial minority of institutional representatives reported adverse effects on research or education and pervasive structural barriers. These perceived impacts on this specialist educational field warrant monitoring to safeguard future workforce capacity.
- Open Access
- 6 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Embryonal Rhabdomyosarcoma of the Diaphragm in a Two-Year-Old Boy
Although primary tumors of the diaphragm are rare in children, rhabdomyosarcoma is the most common malignant tumor arising in the diaphragm. Rhabdomyosarcoma is a malignant tumor that arises from primary mesenchymal cells that differentiate into skeletal muscle. Here, we report on a two-year-old boy in whom embryonal rhabdomyosarcoma of the diaphragm developed and who presented with abdominal distension due to significant ascites. Contrast-enhanced computed tomography revealed two mass lesions: a lesion that had originated from the right diaphragmatic crus, part of the diaphragm, extending to the omental bursa, and another lesion in the left inguinal canal. Furthermore, massive ascites and diffuse peritoneal thickening suggested peritoneal dissemination. On 2-deoxy-2-(fluorine-18)-fluoro-D-glucose positron emission tomography combined with computed tomography, these lesions exhibited high uptake, suggesting malignant tumors. Pathological examination of biopsy specimens of the left inguinal tumor revealed embryonal rhabdomyosarcoma. According to the Intergroup Rhabdomyosarcoma Study IV risk classification system, the patient was categorized as high risk, meeting the criteria for embryonal-type rhabdomyosarcoma, stage 4, and group IV. The ARST0431 therapy was promptly started. Because tumor tissues disappeared on imaging after chemotherapy, surgical resection was omitted. No recurrence has been observed 16 months after the completion of treatment, including chemotherapy and radiotherapy. Even for a group IV rhabdomyosarcoma of the diaphragm, an embryonal type might improve the prognosis with multidisciplinary treatment. Long-term follow-up should carefully monitor not only recurrence but also side effects from the toxicity of total abdominal irradiation.
- 6 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessEmbryonal Rhabdomyosarcoma of the Diaphragm in a Two-Year-Old Boy
Although primary tumors of the diaphragm are rare in children, rhabdomyosarcoma is the most common malignant tumor arising in the diaphragm. Rhabdomyosarcoma is a malignant tumor that arises from primary mesenchymal cells that differentiate into skeletal muscle. Here, we report on a two-year-old boy in whom embryonal rhabdomyosarcoma of the diaphragm developed and who presented with abdominal distension due to significant ascites. Contrast-enhanced computed tomography revealed two mass lesions: a lesion that had originated from the right diaphragmatic crus, part of the diaphragm, extending to the omental bursa, and another lesion in the left inguinal canal. Furthermore, massive ascites and diffuse peritoneal thickening suggested peritoneal dissemination. On 2-deoxy-2-(fluorine-18)-fluoro-D-glucose positron emission tomography combined with computed tomography, these lesions exhibited high uptake, suggesting malignant tumors. Pathological examination of biopsy specimens of the left inguinal tumor revealed embryonal rhabdomyosarcoma. According to the Intergroup Rhabdomyosarcoma Study IV risk classification system, the patient was categorized as high risk, meeting the criteria for embryonal-type rhabdomyosarcoma, stage 4, and group IV. The ARST0431 therapy was promptly started. Because tumor tissues disappeared on imaging after chemotherapy, surgical resection was omitted. No recurrence has been observed 16 months after the completion of treatment, including chemotherapy and radiotherapy. Even for a group IV rhabdomyosarcoma of the diaphragm, an embryonal type might improve the prognosis with multidisciplinary treatment. Long-term follow-up should carefully monitor not only recurrence but also side effects from the toxicity of total abdominal irradiation.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Atypical pulmonary carcinoid in a pediatric patient requiring total pneumonectomy: A case report
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Atypical pulmonary carcinoid in a pediatric patient requiring total pneumonectomy: A case report
- Open Access
- 19 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Pitfalls in Coagulation Testing: A Pediatric Case of Lupus Anticoagulant Hypoprothrombinemia Syndrome Following Enterocolitis
In children, the lupus anticoagulant (LA) is transiently produced after infection and rarely causes bleeding tendency, known as LA-hypoprothrombinemia syndrome (LAHPS). In this case report, we describe a child presenting with difficulty standing and walking after enterocolitis and complicated false coagulation abnormalities. Prolonged prothrombin time and activated partial thromboplastin time (APTT); decreased factors II, VIII, IX, XI, and XII; and inhibitors for factors VIII and IX were detected. On the basis of such findings as inhibitor pattern in the APTT cross-mixing test and positivity for serum LA, LAHPS was diagnosed. Physicians should be aware of the interference by LA with phospholipid-based coagulation tests, leading to the misinterpretation of the unusual coagulation abnormalities in LAHPS.
- 19 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Open AccessPitfalls in Coagulation Testing: A Pediatric Case of Lupus Anticoagulant Hypoprothrombinemia Syndrome Following Enterocolitis
In children, the lupus anticoagulant (LA) is transiently produced after infection and rarely causes bleeding tendency, known as LA-hypoprothrombinemia syndrome (LAHPS). In this case report, we describe a child presenting with difficulty standing and walking after enterocolitis and complicated false coagulation abnormalities. Prolonged prothrombin time and activated partial thromboplastin time (APTT); decreased factors II, VIII, IX, XI, and XII; and inhibitors for factors VIII and IX were detected. On the basis of such findings as inhibitor pattern in the APTT cross-mixing test and positivity for serum LA, LAHPS was diagnosed. Physicians should be aware of the interference by LA with phospholipid-based coagulation tests, leading to the misinterpretation of the unusual coagulation abnormalities in LAHPS.
- Open Access
- 28 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e83147
Life-Threatening Pharyngolaryngeal Hematoma in a Patient With Hemophilia A
Although airway hematomas are a rare complication of hemophilia, emergency treatment is required in these cases since airway obstruction can cause asphyxia. While the main treatment for hematomas in the airway entails replacing the coagulation factor products, in cases with a high risk of asphyxia, deciding whether or not to perform a tracheotomy can be difficult. We report the case of a patient with severe hemophilia A with rapidly worsening dyspnea due to hematomas caused by an acute upper respiratory tract infection and covering the airway at the upper part of the epiglottis and the tongue base. Laryngoscopy revealed a hematoma of the tongue base, but the hypopharynx and larynx were not visible owing to the hematoma. A CT scan also showed narrowing of the airway due to the hematoma. Given the high risk of obstruction, a tracheotomy was performed under general anesthesia. Efraloctocog alfa, a recombinant coagulation factor VIII (FVIII) product with an extended half-life, was administered to maintain trough levels of coagulation FVIII at 80% or above for eight days after tracheotomy. A repeat CT scan performed four days after the tracheotomy confirmed that the hematoma had improved. The patient was discharged 18 days after the tracheotomy with the tracheostoma closed. If patients with hemophilia complain of throat discomfort or dysphagia, the airway should be assessed via laryngoscopy. Emergency tracheotomy and treatment with a recombinant coagulation factor product by a medical team comprising emergency physicians, hematologists, and otolaryngologists is required for hemophilia patients with a high risk of airway obstruction.
- 28 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e83147
Open AccessLife-Threatening Pharyngolaryngeal Hematoma in a Patient With Hemophilia A
Although airway hematomas are a rare complication of hemophilia, emergency treatment is required in these cases since airway obstruction can cause asphyxia. While the main treatment for hematomas in the airway entails replacing the coagulation factor products, in cases with a high risk of asphyxia, deciding whether or not to perform a tracheotomy can be difficult. We report the case of a patient with severe hemophilia A with rapidly worsening dyspnea due to hematomas caused by an acute upper respiratory tract infection and covering the airway at the upper part of the epiglottis and the tongue base. Laryngoscopy revealed a hematoma of the tongue base, but the hypopharynx and larynx were not visible owing to the hematoma. A CT scan also showed narrowing of the airway due to the hematoma. Given the high risk of obstruction, a tracheotomy was performed under general anesthesia. Efraloctocog alfa, a recombinant coagulation factor VIII (FVIII) product with an extended half-life, was administered to maintain trough levels of coagulation FVIII at 80% or above for eight days after tracheotomy. A repeat CT scan performed four days after the tracheotomy confirmed that the hematoma had improved. The patient was discharged 18 days after the tracheotomy with the tracheostoma closed. If patients with hemophilia complain of throat discomfort or dysphagia, the airway should be assessed via laryngoscopy. Emergency tracheotomy and treatment with a recombinant coagulation factor product by a medical team comprising emergency physicians, hematologists, and otolaryngologists is required for hemophilia patients with a high risk of airway obstruction.
- Open Access
- 20 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77747
Development of Neuroblastoma During Growth Hormone Therapy for Short Stature in a Girl With Mosaic Turner Syndrome
We report the case of a girl with mosaic Turner syndrome who developed abdominal neuroblastoma during growth hormone (GH) therapy for short stature. The patient underwent chemotherapy for the unresectable tumor but died at the age of 10 years due to multiple metastases, five years and 10 months after the diagnosis of neuroblastoma. Although the risk of neuroblastoma does not increase in patients with Turner syndrome, the need for pre-treatment imaging studies for tumor screening remains controversial. However, our experience with this patient highlights the potential value of performing imaging studies both before and during GH treatment.
- 20 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77747
Open AccessDevelopment of Neuroblastoma During Growth Hormone Therapy for Short Stature in a Girl With Mosaic Turner Syndrome
We report the case of a girl with mosaic Turner syndrome who developed abdominal neuroblastoma during growth hormone (GH) therapy for short stature. The patient underwent chemotherapy for the unresectable tumor but died at the age of 10 years due to multiple metastases, five years and 10 months after the diagnosis of neuroblastoma. Although the risk of neuroblastoma does not increase in patients with Turner syndrome, the need for pre-treatment imaging studies for tumor screening remains controversial. However, our experience with this patient highlights the potential value of performing imaging studies both before and during GH treatment.
- 25 December 2024
- Published by Wiley in Pediatrics International
- Vol. 67 (1)
A case of epidermoid cyst in which biopsy‐based diagnosis was important in determining treatment for a brainstem tumor
- 25 December 2024
- Published by Wiley in Pediatrics International
- Vol. 67 (1)
A case of epidermoid cyst in which biopsy‐based diagnosis was important in determining treatment for a brainstem tumor
- Open Access
- 16 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75799
Effective Treatment With Oral Propranolol for Congenital Intracranial Hemangioma in a Neonate: A Case Report and Literature Review
Congenital intracranial hemangiomas are rare benign vascular tumors that develop before birth. Although various treatments, including surgery, steroids, interferon-α, thalidomide, bevacizumab, or propranolol, have been reported, no standard therapy has been established. We report the case of a neonate with congenital intracranial hemangioma and central nervous system symptoms requiring therapeutic intervention. Early postnatal oral propranolol treatment was safe and effective. The neurological prognosis is good post-treatment; however, follow-up is needed to determine the long-term neurological prognosis.
- 16 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75799
Open AccessEffective Treatment With Oral Propranolol for Congenital Intracranial Hemangioma in a Neonate: A Case Report and Literature Review
Congenital intracranial hemangiomas are rare benign vascular tumors that develop before birth. Although various treatments, including surgery, steroids, interferon-α, thalidomide, bevacizumab, or propranolol, have been reported, no standard therapy has been established. We report the case of a neonate with congenital intracranial hemangioma and central nervous system symptoms requiring therapeutic intervention. Early postnatal oral propranolol treatment was safe and effective. The neurological prognosis is good post-treatment; however, follow-up is needed to determine the long-term neurological prognosis.
- Open Access
- 13 March 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-7
Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report
Background: Ocular manifestations are known for non-Hodgkin lymphoma, but are rare for Hodgkin lymphoma. We report a case of Vogt-Koyanagi-Harada (VKH) disease presenting as serous retinal detachment and uveitis in both eyes in a child undergoing chemotherapy for Hodgkin lymphoma.Case presentation: The patient was a 7-year-old boy with stage IIB Hodgkin lymphoma (nodular lymphocyte predominant type) who was undergoing chemotherapy, including 2 cycles of the OEPA regimen and 1 cycle of the COPDAC regimen. Two days after the end of the COPDAC regimen, the patient complained of headache and of blurred and decreased vision in both eyes. On the basis of optic symptoms, such as uveitis and serous retinal detachment in both eyes, increased cell counts in cerebrospinal fluid, and positivity for human leukocyte antigen (HLA)-DR4 in peripheral blood cells, incomplete VKH disease was diagnosed. Intravenous treatment with high-dose prednisolone (60mg/m2/day) for 7 days improved both visual acuity and serous retinal detachment and enabled the remains of the COPDAC chemotherapy cycle to be administered. With prednisolone treatment, visual acuity improved from 20/500 to 20/20 in the right eye and from 20/63 to 20/25 in the left eye. Because multiple vitiligo lesions later appeared in the abdomen, complete VKH disease was finally diagnosed.Conclusion: The onset of VKH disease occurred during chemotherapy for Hodgkin lymphoma. The patient was HLA-DR4-positive and might have had a predisposition to develop autoimmune diseases, including VKH disease. However, the anticancer drugs administered to this patient have not been reported to cause uveitis. Whether Hodgkin lymphoma triggered the development of VKH remains unclear. Early diagnosis of VKH disease and prompt treatment with high-dose prednisone enabled the patient to maintain good visual function despite chemotherapy for Hodgkin lymphoma.
- 13 March 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-7
Open AccessVogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report
Background: Ocular manifestations are known for non-Hodgkin lymphoma, but are rare for Hodgkin lymphoma. We report a case of Vogt-Koyanagi-Harada (VKH) disease presenting as serous retinal detachment and uveitis in both eyes in a child undergoing chemotherapy for Hodgkin lymphoma.Case presentation: The patient was a 7-year-old boy with stage IIB Hodgkin lymphoma (nodular lymphocyte predominant type) who was undergoing chemotherapy, including 2 cycles of the OEPA regimen and 1 cycle of the COPDAC regimen. Two days after the end of the COPDAC regimen, the patient complained of headache and of blurred and decreased vision in both eyes. On the basis of optic symptoms, such as uveitis and serous retinal detachment in both eyes, increased cell counts in cerebrospinal fluid, and positivity for human leukocyte antigen (HLA)-DR4 in peripheral blood cells, incomplete VKH disease was diagnosed. Intravenous treatment with high-dose prednisolone (60mg/m2/day) for 7 days improved both visual acuity and serous retinal detachment and enabled the remains of the COPDAC chemotherapy cycle to be administered. With prednisolone treatment, visual acuity improved from 20/500 to 20/20 in the right eye and from 20/63 to 20/25 in the left eye. Because multiple vitiligo lesions later appeared in the abdomen, complete VKH disease was finally diagnosed.Conclusion: The onset of VKH disease occurred during chemotherapy for Hodgkin lymphoma. The patient was HLA-DR4-positive and might have had a predisposition to develop autoimmune diseases, including VKH disease. However, the anticancer drugs administered to this patient have not been reported to cause uveitis. Whether Hodgkin lymphoma triggered the development of VKH remains unclear. Early diagnosis of VKH disease and prompt treatment with high-dose prednisone enabled the patient to maintain good visual function despite chemotherapy for Hodgkin lymphoma.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15501
Referred shoulder pain caused by undifferentiated embryonal sarcoma of the liver
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15501
Referred shoulder pain caused by undifferentiated embryonal sarcoma of the liver